The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism

Chinese Academy of Medical Sciences, Fuwai Hospital392 enrolled

Overview

Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

392

Conditions

COPD Exacerbation PTE - Pulmonary Thromboembolism

Interventions

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized patients due to chronic obstructive pulmonary disease exacerbation and diagnosed as newly developed pulmonary thromboembolism * Regular anticoagulation for 3 months and got CT pulmonary angiography Exclusion Criteria: * Patients with major bleeding during prior anticoagulation * Patients need long term anticoagulation to treat other diseases * Patients unwilling to receive prolonged anticoagulation

Outcomes

Primary Outcomes

Venous thromboembolism recurrence

recurrence rate in %

Time frame: 3 years

Secondary Outcomes

Chronic obstructive pulmonary disease exacerbations

total times

Time frame: 3 year